AGILENT TECHNOLOGIES, INC.
AAPI behind this page
A Q4 2025 request
Playground key active
/api/financials?ticker=A&year=2025&quarter=4
Pick an endpoint and run the request.Income Statement
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Revenue | 1,861 | 1,701 | +9.4% |
Show Product Lines breakouts |
|||
| Instrumentation | 653 | 620 | +5.3% |
| Non-Instrumentation and Other | 1,208 | 1,081 | +11.7% |
| Product | 1,328 | 1,217 | +9.1% |
| Service Other | 533 | 484 | +10.1% |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 755 | 706 | +6.9% |
| Agilent CrossLab · Americas | 290 | 269 | +7.8% |
| Agilent CrossLab · Asia Pacific | 248 | 247 | +0.4% |
| Agilent CrossLab · Europe | 217 | 190 | +14.2% |
| Applied Markets | 351 | 338 | +3.8% |
| Applied Markets · Americas | 102 | 95 | +7.4% |
| Applied Markets · Asia Pacific | 158 | 165 | -4.2% |
| Applied Markets · Europe | 91 | 78 | +16.7% |
| Life Sciences and Diagnostics Markets | 755 | 657 | +14.9% |
| Life Sciences and Diagnostics Markets · Americas | 384 | 316 | +21.5% |
| Life Sciences and Diagnostics Markets · Asia Pacific | 153 | 155 | -1.3% |
| Life Sciences and Diagnostics Markets · Europe | 218 | 186 | +17.2% |
Show Geography breakouts |
|||
| Americas | 776 | 680 | +14.1% |
| Asia Pacific | 559 | 567 | -1.4% |
| Europe | 526 | 454 | +15.9% |
Show End Markets [Axis] breakouts |
|||
| Academia and Government Market | 136 | 150 | -9.3% |
| Diagnostics and Clinical Market | 276 | 255 | +8.2% |
| Environmental and Forensics Market | 180 | 164 | +9.8% |
| Food Market | 165 | 152 | +8.6% |
| Pharmaceutical and Biopharmaceutical Market | 690 | 595 | +16.0% |
| Cost of Revenue | 871 | 785 | +11.0% |
Show Product Lines breakouts |
|||
| Product | 587 | 538 | +9.1% |
| Service Other | 284 | 247 | +15.0% |
| Research & Development | 119 | 111 | +7.2% |
| Selling, General & Administrative | 428 | 397 | +7.8% |
| Total Costs & Expenses | 1,418 | 1,293 | +9.7% |
| Operating Income | 443 | 408 | +8.6% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 246 | 239 | +2.9% |
| Applied Markets · Operating Segments | 87 | 86 | +1.2% |
| Life Sciences and Diagnostics Markets · Operating Segments | 172 | 141 | +22.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 505 | 466 | +8.4% |
| Interest Income | 17 | 24 | -29.2% |
| Interest Expense | -27 | -32 | +15.6% |
| Other Non-Operating Income (Expense) | 9 | 1 | +800.0% |
| Income Before Taxes | 442 | 401 | +10.2% |
| Income Tax Expense (Benefit) | 8 | 50 | -84.0% |
| Net Income | 434 | 351 | +23.6% |
Show Equity Components breakouts |
|||
| Parent | 434 | 351 | +23.6% |
| Retained Earnings | 434 | 351 | +23.6% |
| EPS (Basic) | 1.54 | 1.23 | +25.2% |
| EPS (Diluted) | 1.52 | 1.23 | +23.6% |
| Wtd Avg Shares (Basic) | -1 | -2 | +50.0% |
| Wtd Avg Shares (Diluted) | 0 | -2 | +100.0% |
| Comprehensive Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Parent | 491 | 377 | +30.2% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | 0 | -4 | +100.0% |
Balance Sheet
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,789 | 1,329 | +34.6% |
Show Geography breakouts |
|||
| Non Us | 1,656 | — | — |
| Accounts Receivable | 1,487 | 1,324 | +12.3% |
| Inventory | 1,025 | 972 | +5.5% |
| Other Assets Current | 293 | 334 | -12.3% |
| Total Current Assets | 4,594 | 3,959 | +16.0% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,023 | 1,778 | +13.8% |
| Goodwill | 4,473 | 4,477 | -0.1% |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 1,168 | 1,168 | 0.0% |
| Applied Markets | 309 | 309 | 0.0% |
| Life Sciences and Diagnostics Markets | 2,996 | 3,000 | -0.1% |
| Long Term Investments | 133 | 175 | -24.0% |
| Other Non-Current Assets | 1,059 | 910 | +16.4% |
| Total Assets | 12,727 | 11,846 | +7.4% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Not Primary Beneficiary | 44 | 79 | -44.3% |
| Operating Lease Right-of-Use Assets | 183 | 177 | +3.4% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 445 | 547 | -18.6% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 160 | 184 | -13.0% |
| Developed Technology Rights | 249 | 315 | -21.0% |
| Order Or Production Backlog | 7 | 9 | -22.2% |
| Third-Party Technology and Licenses | 11 | 14 | -21.4% |
| Trademarks | 18 | 25 | -28.0% |
| Current Liabilities | |||
| Accounts Payable | 570 | 540 | +5.6% |
| Employee Related Liabilities Current | 443 | 368 | +20.4% |
| Deferred Revenue | 624 | 544 | +14.7% |
| Short Term Borrowings | 304 | 45 | +575.6% |
Show Debt Instrument breakouts |
|||
| Other Loans | 4 | 5 | -20.0% |
| Other Liabilities Current | 406 | 398 | +2.0% |
| Total Current Liabilities | 2,347 | 1,895 | +23.9% |
| Long-Term Debt | 3,050 | 3,345 | -8.8% |
Show Debt Instrument breakouts |
|||
| Other Loans | 20 | 19 | +5.3% |
| Senior Notes 2027 · Senior Notes | 597 | 596 | +0.2% |
| Senior Notes 2029 · Senior Notes | 497 | 496 | +0.2% |
| Senior Notes 2030 · Senior Notes | 498 | 497 | +0.2% |
| Senior Notes 2031 · Senior Notes | 845 | 845 | 0.0% |
| Senior Notes 2034 · Senior Notes | 593 | 593 | 0.0% |
Show Long-Term Debt Type breakouts |
|||
| Senior Notes | 3,030 | 3,326 | -8.9% |
| Current Portion of Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| Senior Notes 2026 · Senior Notes | 300 | — | — |
| Non-Current Liabilities | |||
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 126 | 130 | -3.1% |
| Other Non-Current Liabilities | 463 | 578 | -19.9% |
| Total Liabilities | 5,986 | 5,948 | +0.6% |
| Operating Lease Liabilities | 145 | 142 | +2.1% |
| Accrued Income Taxes Noncurrent | -28 | -115 | +75.7% |
| Stockholders' Equity | |||
| Common Stock | 3 | 3 | 0.0% |
| Additional Paid-In Capital | 5,575 | 5,450 | +2.3% |
| Retained Earnings | 1,389 | 750 | +85.2% |
| Accumulated Other Comprehensive Income | -226 | -305 | +25.9% |
| Total Stockholders' Equity | 6,741 | 5,898 | +14.3% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -226 | -305 | +25.9% |
| Additional Paid In Capital | 5,575 | 5,450 | +2.3% |
| Common Stock | 3 | 3 | 0.0% |
| Parent | 6,741 | 5,898 | +14.3% |
| Retained Earnings | 1,389 | 750 | +85.2% |
| Total Liabilities & Equity | 12,727 | 11,846 | +7.4% |
Cash Flow Statement
| Metric | YTD Q4 2025 | YTD Q4 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 71 | 69 | +2.9% |
| Stock-Based Compensation | 26 | 26 | 0.0% |
| Deferred Income Taxes | -95 | -56 | -69.6% |
| Inventory Write Down | 15 | 12 | +25.0% |
| Equity Securities Fv Ni Gain Loss | -8 | 0 | — |
| Other Non-Cash Items | 1 | -3 | +133.3% |
| Change in Accounts Receivable | -105 | -60 | -75.0% |
| Change in Inventory | -25 | 19 | -231.6% |
| Change in Accounts Payable | 29 | 25 | +16.0% |
| Increase Decrease In Employee Related Liabilities | 95 | 53 | +79.2% |
| Increase Decrease In Other Operating Capital Net | 91 | 34 | +167.6% |
| Net Cash from Operations | 545 | 481 | +13.3% |
| Investing Activities | |||
| Capital Expenditures | -93 | -93 | 0.0% |
| Payments To Acquire Notes Receivable | 0 | -2 | +100.0% |
| Payments To Acquire Businesses Net Of Cash Acquired | 0 | -859 | +100.0% |
| Net Cash from Investing | -90 | -954 | +90.6% |
| Financing Activities | |||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 12 | 1 | +1100.0% |
| Tax Withholding for Share Compensation | 1 | 3 | -66.7% |
| Share Repurchases | -85 | -335 | +74.6% |
| Payments Of Dividends Common Stock | -70 | -68 | -2.9% |
| Repayments Of Long Term Debt | -1 | -420 | +99.8% |
| Proceeds From Repayments Of Short Term Debt | -55 | -335 | +83.6% |
| Net Cash from Financing | -200 | 25 | -900.0% |
| Supplemental | |||
| Income Taxes Paid | 14 | 30 | -53.3% |
| Interest Paid | 46 | 30 | +53.3% |
| Share Repurchase Program Excise Tax Payable | 3 | 10 | -70.0% |
| Other Cash Flow | |||
| Net Change in Cash | 254 | -450 | +156.4% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,791 | 1,332 | +34.5% |
Values in millions USD. Source: SEC EDGAR 10-K filing.